<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01968044</url>
  </required_header>
  <id_info>
    <org_study_id>LG-DPCL015</org_study_id>
    <nct_id>NCT01968044</nct_id>
  </id_info>
  <brief_title>A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)</brief_title>
  <acronym>GUARD</acronym>
  <official_title>A Multicenter,Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase IIIb Study to Evaluate the Safety and Efficacy After 12 Weeks Administration of Gemigliptin and Placebo in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment With an Additional 40 Weeks, Double-blind,Active-controlled, Double-dummy,Long-term Extension Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <brief_summary>
    <textblock>
      Therapuetic options are limited for Type 2 Diabetes Mellitus (T2DM) pateints with renal
      impairment. This clinical study is to asses safety and efficacy of the DPP-4 inhibitor
      gemigliptin in patients with type 2 DM and moderate or severe renal impairment for long-term
      peirod (52 weeks).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c change</measure>
    <time_frame>HbA1c change from baseline to week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change</measure>
    <time_frame>HbA1c change from baselint to week 6, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FPG</measure>
    <time_frame>FPG change from baseline to week 6,12,52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated albumin</measure>
    <time_frame>Glycated albumin change from baseline to week 6,12,52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fructosamin</measure>
    <time_frame>Fructosamin change from baseline to week 6,12,52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist</measure>
    <time_frame>Waist change from baseline to week 12,52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c responser (HbA1c&lt;7.0%)</measure>
    <time_frame>HbA1c responser rate at week 12,52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum C-peptide</measure>
    <time_frame>Fasting serum C-peptide change from baseline to week 12,52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Lipid parameters</measure>
    <time_frame>Fasting Lipid parameters change from baseline to week 12,52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albuminuria</measure>
    <time_frame>Albuminuria change from baseline to week 12,52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Type 2 DM Patients With Moderate or Severe Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Gemigliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will remain gemigliptin 50mg throughout entire study (52 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to linagliptin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participant who is randomized to placebo will be switched to linagliptin after 12 week and administered linagliptin by week 52.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin</intervention_name>
    <arm_group_label>Gemigliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Linagliptin</intervention_name>
    <arm_group_label>Placebo to linagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Type 2 Diabetes Mellitus

          -  Patients with moderate or severe renal insufficiency

          -  All patients give written informed consent

        Exclusion Criteria:

          -  Has type 1 diabetes mellitus or a history of ketoacidosis

          -  Is on dialysis or is likely to need dialysis during the study

          -  Has active liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DR Cha, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2013</study_first_posted>
  <last_update_submitted>March 21, 2016</last_update_submitted>
  <last_update_submitted_qc>March 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

